A bipartisan group of lawmakers are pushing for bipartisan legislation that would both lower insulin prices and prohibit drug rebates for insulin. One of the top priorities of the lawmakers is to cap insulin out-of-pocket costs at $35 per month (between deductible and any cost sharing) and to support patient access to insulin by ensuring prior authorization or other similar formulary management tools “cannot be imposed to limit beneficiary use.” Another priority of the group is to ensure that plans and pharmacy benefit managers (PBMs) “cannot collect rebates, which drive up drug costs at the point of sale, on insulins that roll prices back to 2006 or equivalent levels.” Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME) released a joint statement, saying that their “proposal holds all parties accountable by encouraging them to reduce list prices, and critically, it limits out-of-pocket costs for patients with diabetes.” Representatives Diana Degette (D-CO) and Tom Reed (R-NY) also joined the announcement. Senators Shaheen and Collins co-chair the Senate Diabetes Caucus while Degette and Reed co-chair the House Diabetes Caucus.
Print Page
Email to a Friend